startup.bid
EN
EnglishEspañolPortuguêsFrançaisDeutschItalianoNederlandsSvenskaDanskNorskPolskiSlovenščinaTürkçeРусскийBahasa IndonesiaBahasa MelayuFilipinoTiếng ViệtKiswahiliहिन्दीاردوالعربيةעברית日本語한국어中文繁體中文

zPREDICTA

Patient-derived 3D tissue reconstruction models for preclinical…

Acquired

About

zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic.

Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications.

Topics

Location
San Francisco, CA, United States
Team size
2 employees
YC batch
Summer 2015
Status
Acquired
Stage
Early stage

Similar startups & competitors

Questions and answers

What does zPREDICTA do?

Patient-derived 3D tissue reconstruction models for preclinical…

Where is zPREDICTA based?

San Francisco, CA, United States

How many people work at zPREDICTA?

2 employees, according to the company profile.

Has zPREDICTA raised money?

There are no funding rounds for zPREDICTA in our data.

What are the alternatives to zPREDICTA?

Similar startups: Numerion Labs, Verge Genomics, and PostEra.